E
CRNX icon

Ergoteles’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ergoteles’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,839
Closed -$412K – 227
2023
Q2 		$412K Buy
22,839
+6,682
+41% +$133K 0.02% 684
2023
Q1 		$259K Sell
16,157
-2,927
-15% -$54.2K 0.01% 934
2022
Q4 		$349K Buy
+19,084
New +$336K 0.01% 858

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ergoteles's CRNX Position: Q3 2023 in Review

Ergoteles sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2023, closing a stake of 22,839 shares — an estimated $412K sold.

Ergoteles first reported a position in CRNX in Q4 2022 and held it in 3 quarters. The position peaked at $412K in Q2 2023. 171 funds tracked by Wall St. Rank hold CRNX as of Q3 2023.

  • Ergoteles reported no remaining Crinetics Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 22,839 Crinetics Pharmaceuticals shares in Q3 2023, an estimated $412K.
  • Ergoteles first reported a position in Crinetics Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Ergoteles's Crinetics Pharmaceuticals position peaked at $412K in Q2 2023.
  • 171 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.